Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 16/20 | 0.77 |
| ▸ | GABRG2 | P18507 | 16/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 16/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 13/20 | 0.77 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.58 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142451 | 1.00 | GABRA3 (0.77) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL7723524 | 1.00 | GABRA3 (0.77) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL13523903 | 1.00 | GABRA3 (0.77) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL13523906 | 0.90 | GABRA5 (0.62) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL7726226 | 0.90 | GABRA5 (0.62) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL3142378 | 0.90 | GABRA5 (0.62) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL7722541 | 0.89 | GABRA5 (0.80) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL3142332 | 0.89 | GABRA5 (0.80) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL7718310 | 0.89 | GABRA5 (0.80) | GABRA3GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL19877937 | 0.88 | GABRA3 (0.66) | GABRA3GABRG2GABRB3GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374612-A1 | IMIDAZOBENZODIAZEPINES FOR TREATMENT OF COGNITIVE AND MOOD SYMPTOMS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374612-A1 | IMIDAZOBENZODIAZEPINES FOR TREATMENT OF COGNITIVE AND MOOD SYMPTOMS | GRIN2D, GRIN2C, HTR2C | GABRA3 16/4885GABRG2 79/4885GABRB3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.